Results
F-araA PK showed wide inter-individual variation (27 and 19 fold in
F-araA AUC and CL) which was explained by a promoter polymorphism
(rs2295890) in the NT5E gene. Patients carrying the NT5Epromoter variant showed no graft rejection (0% vs 7.7%, p=0.07) or
Sinusoidal Obstruction Syndrome (0% Vs 19%, p=0.0007) and a trend to
better EFS (87.5% vs 75.7%, p=0.1). F-araA systemic exposure was not
associated with HCT outcome.